<DOC>
	<DOC>NCT00246974</DOC>
	<brief_summary>The primary objective of the study is to assess the activity of ZD1839 250 mg once daily in addition to the standard chemotherapy in patients with advanced or metastatic transitional cell carcinoma of the urothelium by estimating the time to progression.</brief_summary>
	<brief_title>Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically or cytologicallyconfirmed transitional cell carcinoma of the urothelium Locally advanced or metastatic disease At least one measurable lesion as defined by RECIST Chemotherapynaiv Previous chemotherapy or other systemic antitumour therapy Other coexisting malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma, cervical cancer in situ or locally limited prostate cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>bladder cancer</keyword>
	<keyword>Transitionel cell cancer of the urothelium</keyword>
</DOC>